ClinicalTrials.gg
RecruitingNCT07135895Updated Nov 9, 2026

The ArtixASCEND Study

An interventional study of Artix Thrombectomy System in Acute Lower Limb Arterial Occlusion, sponsored by Inari Medical. Recruiting at 26 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Inari Medical (part of Stryker) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 9, 20264 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is a post-market, prospective, multicenter, single-arm study to evaluate the safety and effectiveness of the Artix Thrombectomy System in patients with acute lower extremity arterial occlusions.

02

Conditions studied

  • Acute Lower Limb Arterial Occlusion

Keywords

  • Acute Limb Ischemia
  • Lower limb arterial occlusion
  • Artix Thrombectomy System
03

In context

Lead sponsor

Inari Medical is the lead sponsor of 14 studies on the registry; 6 are open to participants now.

First submitted after Inari Medical became part of Stryker.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Acute symptom duration ≤ 14 days
  • Lower limb arterial occlusion below inguinal ligament
  • Target lesion in native vessel
  • Target vessel size between 3 mm and 8 mm by visual estimation
  • Rutherford category I, IIa, or IIb
  • is obtained from either patient or legally authorized representative (LAR) per Institutional Review Board/Ethics Committee requirements

Exclusion criteria

Exclusion Criteria:

  • \< 6 months
  • Prior major amputation in the target limb
  • Prior minor amputation in the target limb that is not completely healed or cannot bear weight
  • Non-thrombotic occlusion secondary to dissection, vasculitis, or target vessel trauma
  • Treatment of the index event in the target vessel with any other endovascular thrombectomy/aspiration or open surgical method prior to Artix procedure
  • Part of a vulnerable population (e.g., currently pregnant, breastfeeding or incarcerated) per local definitions
  • Known sensitivity to radiographic contrast agents that, in the Investigator's opinion, cannot be adequately pre-treated
  • Unable to tolerate antiplatelet therapy
  • Inability to anticoagulate the patient with heparin, enoxaparin or other parenteral antithrombin, or known to have uncorrected bleeding disorders (e.g., gastro-intestinal ulcer, menorrhagia, liver failure, heparin-induced thrombocytopenia (HIT))
  • Any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject (e.g., to use of Artix per local approved labeling, compromise the well-being or that could prevent, limit, or confound the protocol-specified assessments)
  • Current participation in another drug or device study that, in the investigator's opinion, would interfere with participation in this study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Artix Thrombectomy System

    Non-surgical removal of lower extremity arterial emboli and thrombi using the Artix Thrombectomy System.

    Device: Artix Thrombectomy System

Interventions

  • DeviceArtix Thrombectomy System

    Treatment of lower extremity arterial occlusions using the Artix Thrombectomy System.

06

What researchers measure

Primary outcomes

  1. Primary Effectiveness Endpoint

    Revascularization rate post-index procedure of target treatment area determined by an independent core lab.

    Time frame: Immediately Following Index Procedure

  2. Primary Safety Endpoint

    Periprocedural (within 48 hours) Artix Thrombectomy System-related major bleeding rate adjudicated as causal to the study device as determined by an independent Medical Monitor.

    Time frame: 48 Hours

Secondary outcomes

  1. Distal embolization SAEs

    Time frame: Intra-procedure

  2. All-cause mortality

    Time frame: 1-month follow-up visit

  3. Limb salvage

    Freedom from major amputation of the index limb

    Time frame: 1-month follow-up visit

  4. Amputation-free survival

    Freedom from major amputation and all-cause mortality

    Time frame: 1-month follow-up visit

07

Study locations

26 of 26 sites recruiting
  • California Pacific Medical Center Van Ness/Sutter Health
    San Francisco, California 94109, United States
    Recruiting
    • Hernan Bazan, MD · Contact
  • Yale University
    New Haven, Connecticut 06510, United States
    Recruiting
    • Edouard Aboian, MD · Contact
  • MedStar Washington Hospital Center
    Washington D.C., District of Columbia 20010, United States
    Recruiting
    • Kyle Reynolds, MD · Contact
  • Ascension Sacred Heart Pensacola
    Pensacola, Florida 32504, United States
    Recruiting
    • Rohit Amin, MD · Contact
  • Terrebonne General Hospital/Cardiovascular Institute of the South
    Houma, Louisiana 70360, United States
    Recruiting
    • Pradeep Nair, MD · Contact
  • University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
    Recruiting
    • Saurabh Gupta, MD · Contact
  • Mass General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
    • Anahita Dua, MD · Contact
  • MyMichigan Health
    Midland, Michigan 48670, United States
    Recruiting
    • Jacob Frisbie, DO · Contact
  • Cooper University Hospital
    Camden, New Jersey 08103, United States
    Recruiting
    • Bruce Tjaden Jr, MD · Contact
  • NYP-Brooklyn Methodist Hospital
    Brooklyn, New York 11215, United States
    Recruiting
    • Rajesh K Malik, MD · Contact
  • Mount Sinai Medical Center NY
    New York, New York 10025, United States
    Recruiting
    • Michael Dudkiewicz, MD · Contact
  • Vassar Brothers Medical Center/Nuvance Health
    Poughkeepsie, New York 12601, United States
    Recruiting
    • Zachary Matthay, MD · Contact
  • Stony Brook University Hospital
    Stony Brook, New York 11794, United States
    Recruiting
    • Angela Kokkosis, MD · Contact
  • Mission Memorial Hospital
    Asheville, North Carolina 28801, United States
    Recruiting
    • John Henretta, MD · Contact
  • Aultman Hospital
    Canton, Ohio 44710, United States
    Recruiting
    • Jeffrey Prem, MD · Contact
  • The Christ Hospital
    Cincinnati, Ohio 45219, United States
    Recruiting
    • Christopher Paprzycki, MD · Contact
  • Ascension St. John Jane Phillips Medical Center
    Bartlesville, Oklahoma 74006, United States
    Recruiting
    • Anderson Mehrle, MD · Contact
  • Saint Francis Hospital
    Tulsa, Oklahoma 74136, United States
    Recruiting
    • Andres Andres Guerra, MD · Contact
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Shang Loh, MD · Contact
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
    Recruiting
    • Satish Muluk, MD · Contact
  • Grand Strand Medical Center
    Myrtle Beach, South Carolina 29572, United States
    Recruiting
    • Christian Salinas, MD · Contact
  • Spartanburg Regional Health System
    Spartanburg, South Carolina 29303, United States
    Recruiting
    • Scott Silver, MD · Contact
  • TriStar Centennial Medical Center
    Nashville, Tennessee 37203, United States
    Recruiting
    • Allen Lee, MD · Contact
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
    Recruiting
    • Ziad Al Adas, MD · Contact
  • HCA Houston Healthcare Medical Center
    Houston, Texas 77004, United States
    Recruiting
    • Kristofer Charlton-Ouw, MD · Contact
  • Bellin Health
    Green Bay, Wisconsin 54301, United States
    Recruiting
    • Sumit Ringwala, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Mar 2029, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2025
First posted
Aug 22, 2025
StartActual
Jan 7, 2026
Primary completionEst.
Mar 1, 2029
CompletionEst.
Oct 1, 2029
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added
Show 4 added (4 United States)
  • Mount Sinai Medical Center NY · New York, United States
  • University of Maryland Medical Center · Baltimore, United States
  • University of Pennsylvania · Philadelphia, United States
  • Vanderbilt University Medical Center · Nashville, United States
across 2 updates, Oct 13, 2026 – Nov 9, 2026
Show all 2 updates
  1. Nov 9, 2026
    3 sites added
    Show 3 added (3 United States)
    • University of Maryland Medical Center · Baltimore, United States
    • University of Pennsylvania · Philadelphia, United States
    • Vanderbilt University Medical Center · Nashville, United States
    + 2 other changes: verification date and contact details
  2. Oct 13, 2026
    1 site added
    Show site
    • Mount Sinai Medical Center NY · New York, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07135895
Lead sponsor
Inari Medical
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Jan 7, 2026
Primary completion
Mar 1, 2029 (estimated)
Completion
Oct 1, 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

James Allen
Contact
james.allen2@stryker.com
651-279-8587
Chris Ottaviano
Contact
chris.ottaviano@stryker.com
609-634-4571
Anahita Dua, MD
principal investigator · Massachusetts General Hospital
Shang Loh, MD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion